Demonstration of antibody evasion mechanisms and applicability to metastatic cancer
[by Yu, Suin] SillaJen announced on January 27 that the research findings related to its next-generation anticancer platform technology, ‘SJ-650,’ currently under development, have been accepted for publication in ‘Molecular Therapy,’ a leading international journal in the field of molecular therapy.
Molecular Therapy, the official journal of the American Society for Gene and Cell Therapy (ASGCT) and a leading publication in gene and cell therapy issued by Cell Press, is recognized as a top-tier journal in the field. With an impact factor (IF) exceeding 12, it is known for its rigorous standards, requiring not only technological excellence but also clear potential for clinical scalability. SillaJen explained that the acceptance of this study represents formal recognition by the international academic community of both the innovative nature and scientific validity of 바카라사이트 벳위즈650 technology.
바카라사이트 벳위즈650 overcomes key limitations of existing oncolytic virus therapies, which have shown restricted efficacy when administered intravenously due to rapid clearance by the complement system and neutralizing antibodies. It has the unique feature of being a systemically deliverable oncolytic virus engineered to express the complement regulatory protein CD55 on the virus surface, thereby enabling stable circulation and effective delivery to tumor tissues even in an active immune environment. This design is regarded as a significant technological breakthrough, as it overcomes the structural constraints of conventional oncolytic viruses that depend primarily on direct intratumoral injection.
The accepted paper, titled ‘CD55-displaying oncolytic vaccinia virus treated metastatic cancers by evading the effect of host innate and adaptive humoral responses,’ was jointly conducted by the research team led by Professor Lee Dong-sup of Seoul National University College of Medicine and scientists from SillaJen. In this work, the researchers identified the mechanism by which SJ-650 selectively accumulates in tumor tissues and exerts potent antitumor activity even in the presence of neutralizing antibodies, and demonstrated robust anticancer efficacy in metastatic cancer models.
Of particular note, the neutralizing antibody-evasion mechanism of 바카라사이트 벳위즈650 was directly validated through experiments using patient-derived serum containing vaccinia virus-specific antibodies. This findings demonstrates that the underlying mechanism of action is not confined to animal models but is reproducible under conditions that closely reflect the human immune environment.
Furthermore, the team demonstrated that antitumor efficacy was maintained without diminishing even after repeated administration. This finding addresses a fundament limitation of conventional oncolytic virus therapies, namely, the restricted number of feasible dosing cycle, and represents a meaninfsul advantage by enabling sustained long-term treatment as well as combination therapeutic strategies. In addition, the confirmed efficacy in metastatic cancer models is expected to support indication expansion thereby increasing the value of the pipeline and broadening its commercial marketability.
"Acceptance of this study by one of the world's most authoritative journals provides objective validation of the technological perfection and global competitiveness of SJ-650. Going forward, the company will continue to concentrate its capabilities on developing a next-generation oncolytic virus pipeline based on the GEEV (Genetically Engineered Enveloped Virus) platform, with SJ-650 as a core asset," a SillaJen official said.
Conversely, SillaJen is currently working in collaboration with ReiThera, a global contract development and manufacturing organization (CDMO) headquartered in Italy, to develop a clinical-grade manufacturing process for 바카라사이트 벳위즈650 and to support its large-scale drug production in preparation for clinical trials.